GALNT14 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7980209	1.00	1/20
SCHEMBL29370098	1.00	1/20
SCHEMBL26768213	0.79	1/20
SCHEMBL7987277	0.69	1/20
SCHEMBL2357304	0.68	1/20
SCHEMBL29466713	0.68	1/20
SCHEMBL29827270	0.68	1/20
SCHEMBL17949557	0.66	1/20
SCHEMBL7984298	0.66	1/20
SCHEMBL9748319	0.61	1/20
SCHEMBL21517158	0.61	1/20
SCHEMBL3874869	0.61	1/20
SCHEMBL15285080	0.61	1/20
SCHEMBL31414410	0.61	1/20
SCHEMBL7330918	0.60	1/20
SCHEMBL22431062	0.59	1/20
SCHEMBL1444851	0.58	1/20
SCHEMBL30451609	0.58	1/20
SCHEMBL5351976	0.58	1/20
SCHEMBL7227954	0.57	1/20

Clinical trials — most relevant to GALNT14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy	PHASE2	COMPLETED
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC	nan	RECRUITING
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
The Natural History of Sialidosis Type I	nan	RECRUITING
Registry Gangliosidoses	nan	UNKNOWN
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain	nan	UNKNOWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GALNT14 binder may also engage these)

Protein	Name	Similarity
Q8BVG5	—	1.000	Q8BVG5 →
Q8CF93	—	1.000	Q8CF93 →
Q29121	—	1.000	Q29121 →
Q8MV48	—	1.000	Q8MV48 →
O08912	—	0.999	O08912 →
GALNT1	Polypeptide N-acetylgalactosaminyltransferase 1	0.999	landscape →
GALNT13	Polypeptide N-acetylgalactosaminyltransferase 13	0.999	landscape →
Q6UE39	—	0.998	Q6UE39 →
S5S833	—	0.997	S5S833 →
Q5EA41	—	0.997	Q5EA41 →
Q8C7U7	—	0.997	Q8C7U7 →
Q921L8	—	0.997	Q921L8 →
Q6P6V1	—	0.997	Q6P6V1 →
Q6WV20	—	0.997	Q6WV20 →
GALNT3	Polypeptide N-acetylgalactosaminyltransferase 3	0.997	landscape →
P70419	—	0.997	P70419 →
Q8N428	—	0.996	Q8N428 →
Q6WV17	—	0.996	Q6WV17 →
Q07537	—	0.996	Q07537 →
Q9JJ61	—	0.996	Q9JJ61 →
Q8IXK2	—	0.996	Q8IXK2 →
O61394	—	0.996	O61394 →
H0ZAB5	—	0.996	H0ZAB5 →
Q10473	—	0.996	Q10473 →
Q8N4A0	—	0.995	Q8N4A0 →
Q9D4M9	—	0.995	Q9D4M9 →
Q6DJR8	—	0.995	Q6DJR8 →
GALNT10	Polypeptide N-acetylgalactosaminyltransferase 10	0.995	landscape →
O08832	—	0.995	O08832 →
Q8NCW6	—	0.994	Q8NCW6 →